Next Article in Journal
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy
Next Article in Special Issue
Dendritic Cell Regulation by Cannabinoid-Based Drugs
Previous Article in Journal
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
Previous Article in Special Issue
The Role of Cannabinoid Receptors in the Descending Modulation of Pain
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(8), 2689-2708; doi:10.3390/ph3082689

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

University Hospital of Psychiatry, Bolligenstrasse 111, 3000 Bern 60, Switzerland;
*
Author to whom correspondence should be addressed.
Received: 23 June 2010 / Revised: 5 August 2010 / Accepted: 16 August 2010 / Published: 17 August 2010
(This article belongs to the Special Issue Cannabinoids)
View Full-Text   |   Download PDF [98 KB, uploaded 17 August 2010]

Abstract

The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD) and vascular dementia (VD). Numerous studies have demonstrated an involvement of the cannabinoid system in neurotransmission, neuropathology and neurobiology of dementias. In addition, several candidate compounds have demonstrated efficacy in vitro. However, some of the substances produced inconclusive results in vivo. Therefore, only few trials have aimed to replicate the effects seen in animal studies in patients. Indeed, the literature on cannabinoid administration in patients is scarce. While preclinical findings suggest causal treatment strategies involving cannabinoids, clinical trials have only assessed the suitability of cannabinoid receptor agonists, antagonists and cannabidiol for the symptomatic treatment of dementia. Further research is needed, including in vivo models of dementia and human studies. View Full-Text
Keywords: cannabinoids; Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; vascular dementia cannabinoids; Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; vascular dementia
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Walther, S.; Halpern, M. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals 2010, 3, 2689-2708.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top